【正文】
15 (3): 23143 LDL Reduction with mg of Cerivastatin 90 80 70 60 50 40 30 20 10 0 ? 30 ? 35 ? 40 ? 45 Cumulative % of respondents LDL Responder Rates with mg LDL % reduction rates in patients aged 60 to 65 years (n = 156) Data on file 0,0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 16,0 18,0 50 40 30 HDL baseline HDL Responder Rates 50 % HDL increase Data on file mg responder rate at 8 weeks 90 80 70 60 50 40 30 20 10 0 ? 10 ? 20 ? 30 ? 40 ? 50 TG responder rates for mg TG % reduction rates from baseline ? 300 mg/dl at 8 weeks ( n = 43) Cumulative % of respondents Data on file 20 10 0 30 40 5 placebo Baseline triglycerides 150 mg/dl 150250 mg/dl 250 mg/dl 10 35 25 15 5 TG Reduction STEIN E et al. Atherosclerosis 1999。 16 (2):8087 LDLC (mean % change from baseline after 24 weeks) 10 40 30 20 10 0 50 % Men ( n = 200) Women ( n = 102) % LDL Cholesterol Reduction From Baseline OSE et al. Curr Med Res amp。nster, Germany The Lipid Triad Expert Comments The Impact of Guidelines Part V The Lipid Triad What the NCEP * Guidelines Say HDL Cholesterol ? 35 mg/dl ( mmol/l) LDL Cholesterol ? 100 mg/dl ( mmol/l) TG ? 200 mg/dl ( mmol/l) * National Cholesterol Education Program targets for secondary prevention The LDL/HDL Ratio What the Guidelines say Secondary Prevention Guidelines NCEP (USA) LDL/HDL Association of Cardiology (Germany) LDL/HDL Society of Lipid Therapy (Germany) LDL/HDL 3 Cerivastatin Clinical Data Part VI Change in LDL/HDL Ratio Datapool analysis, 8 weeks 0 1 2 3 4 5 Baseline n = 459 n = 636 n = 645 n = 1072 n = 732 LDL/HDL Ratio Data on file 50 45 40 35 30 25 20 15 10 5 0 % Change in LDL/HDL Ratio Datapool analysis, 8 weeks % Change in LDL/HDL Ratio Placebo Data on file Baseline LDL/HDL ratio After 8 weeks % of respondents ? 5 ? 5